[144] Thermo Fisher Scientific, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Thermo Fisher Scientific, Inc. (TMO): An owner proposes to sell 11,440 common shares through Fidelity Brokerage Services on the NYSE with an approximate sale date of 08/19/2025. The filing reports an aggregate market value of $5,671,128.27 and a total of 377,612,121 shares outstanding, and indicates the shares were acquired under an option granted on 09/09/2020 with the acquisition dated 08/19/2025. Payment for the sale is listed as cash. The filer certifies they are not aware of any undisclosed material adverse information and notes there were no sales in the past three months by the same person.

Positive

• Rule 144 disclosure filed, ensuring regulatory transparency for insider-originated sale
• No sales in the past three months by the same person, suggesting no accelerated divestiture pattern
• Filer affirms no undisclosed material adverse information, a standard compliance representation

Negative

• Proposed sale value of $5,671,128.27 represents a sizeable dollar amount even if small versus shares outstanding
• Sale originates from exercised option granted in 2020, which may prompt questions about insider liquidity timing

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice for an insider-originated option sale; size is immaterial relative to total shares outstanding.

The filing discloses a proposed sale of 11,440 common shares via a broker on the NYSE with an aggregate market value of $5.67 million. Relative to the reported 377,612,121 shares outstanding, the lot represents approximately 0.003% of outstanding shares, indicating limited direct dilution or market impact. The securities were acquired via an option granted 09/09/2020 and the payment method for the resale is cash. No other sales by the same person in the prior three months are reported. This appears to be a compliance-driven disclosure under Rule 144 rather than a material corporate event.

Corporate Governance Expert

TL;DR: Form 144 documents a controlled disposition under Rule 144 with the filer affirming absence of undisclosed material information.

The notice includes the required representation that the seller does not possess undisclosed material adverse information, which is standard for such filings. The acquisition history identifies an option grant date in 2020 and a same-day acquisition/sale date in 2025, consistent with an exercise-and-sale transaction. The absence of other recent sales reduces concern about accelerated insider divestiture. From a governance perspective, the filing meets disclosure obligations and raises no immediate compliance red flags based on the information provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	11440	5671128.27	377612121	08/19/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/19/2025	Option Granted - 09/09/2020	Issuer			11440	08/19/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Thermo Fisher Scientific (TMO) disclose?

The filing discloses a proposed sale of 11,440 common shares via Fidelity on the NYSE with an aggregate market value of $5,671,128.27 and an approximate sale date of 08/19/2025.

Who is the broker handling the proposed sale listed in the Form 144?

Fidelity Brokerage Services LLC (address shown in the filing) is listed as the broker for the proposed sale.

When were the securities acquired according to the Form 144?

The securities are reported as acquired on 08/19/2025 following an option grant dated 09/09/2020, and the payment method for the resale is listed as cash.

Does the Form 144 report any other sales by this person in the past three months?

No. The filing states 'Nothing to Report' for securities sold during the past three months.

How large is the proposed sale relative to outstanding shares?

The filing reports 377,612,121 shares outstanding; the proposed sale of 11,440 shares represents roughly 0.003% of that total based on the reported figures.

Does the filer assert possession of any undisclosed material information?

The filer represents they do not know any material adverse information regarding the issuer that has not been publicly disclosed, per the certification in the filing.